Remove 2003 Remove Compounding Remove Pharmaceutical Companies
article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. Org Process Res Dev 2020, 24, 10, 1996–2003.

article thumbnail

Molecular Farming: Paving a Modern Track for Pharmaceutical Sectors (Molecular Pharming)

PharmaShots

After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceutical companies. With unprecedented diseases lurking on the corner, pharmaceutical companies, are now obligated to widen their conventional horizons and look for substitute practices in their drug development strategies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Beating the Big C

Pharmaceutical Technology

The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. ” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.”

article thumbnail

Unlocking disease treatment with large-scale research

pharmaphorum

A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped. The power of AI is also being harnessed to sift through vast amounts of data to determine potential areas of treatment or to discover new uses for old compounds.

article thumbnail

CMC Requirements for New Drug Registration in Latin America

ISPE

In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceutical companies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements. Published February 2003. Published February 2003.